Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Direct Factor Xa Inhibitor YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement.---A Double Blind, Parallel, Dose-finding Study in Comparison With Open Label Enoxaparin

NCT00353678 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00353678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00353678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Direct Factor Xa Inhibitor YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement.---A Double Blind, Parallel, Dose-finding Study in Comparison With Open Label Enoxaparin
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2006
Completion date
August 31, 2007
Enrollment
1,141 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

thromboembolism